About - SENS :

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Employees - 117, CEO - Timothy T. Goodnow, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -9.62, Piotroski Score(max is 10): 4, Working Capital: $93185000, Total Assets: $126269000, Retained Earnings: $-1016987000, EBIT: -56516000, Total Liabilities: $65223000, Revenue: $36905000

- Current Price $ - Analyst Target Price $

Stats & Key Metrics
TickerSENS
Index
Curent Price
Change
Market Cap
Average Volume
Income
Sales
Book Value/Share
Cash/Share
Dividend Est
Dividend TTM
Dividend Ex-Date
Employees
Moving Avg 20days
Moving Avg 50days
Moving Avg 200days
Shares Outstanding
Earnings Date
Inst. Ownership
Key Ratios & Margins
Price/Earnings
Forwad P/E
PE Growth
Price/Sales
Price/Book
Price/Cash
Price/FCF
Quick Ratio
Current Ratio
Debt/Equity
Return on Assets
Return on Equity
Return on Investment
Gross Margin
Ops Margin
Profit Margin
RSI
BETA(β)
From 52week Low
From 52week High
Earnings & Valuation
EPS
EPS next Year
EPS next Qtr
EPS this Year
EPS next 5 Year
EPS past 5 Year
Sales past 5 Year
EPS Y/Y
Sales Y/Y
EPS Q/Q
Sales Q/Q
Sales Surprise
EPS Surprise
ATR(14)
Perf Week
Perf Month
Perf Quarter
Perf Year
Perf YTD
Target Price

AryaFin Engine© - An AI FinTech Venture - 2024-26 Disclaimer